Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

88 results about "Keyhole-limpet haemocyanin" patented technology

Keyhole limpet hemocyanin (KLH) is a large, multisubunit, oxygen-carrying, metalloprotein that is found in the hemolymph of the giant keyhole limpet, Megathura crenulata, a species of keyhole limpet that lives off the coast of California, from Monterey Bay to Isla Asuncion off Baja California.

Method of preparing bombyx mori silk fibroin specific antibody by utilizing characteristic polypeptide

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic polypeptide. The method comprises the following steps: synthesizing a "CGAGAGSGAGAGS" polypeptide sequence by utilizing an Fmoc method, coupling the polypeptide with keyhole limpet hemocyanin (KLH) through the cysteine on the N terminus of the polypeptide so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain a primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antibody titer in the rabbit blood sample reaches 1/10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate.
Owner:ZHEJIANG UNIV +1

Phosphorylcholine Conjugates and Corresponding Antibodies

IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure>95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high IgM autoantibodies to phosphorylcholine. The presence or absence of IgM autoantibodies against phosphorylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determine IgM antibodies toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of IgM antibodies can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or a monoclonal antibody with specificity to a phosphorylcholine conjugate (passive immunization) is proposed and the use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis.
Owner:ATHERA BIOTECH

Method of preparing bombyx mori silk fibroin specific antibody by utilizing characteristic dodecapeptide

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic dodecapeptide. The method comprises the following steps: synthesizing a polypeptide with a "CGYGAGAGAGYGA" sequence, coupling the polypeptide with keyhole limpet hemocyanin (KLH) so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, carrying out an emulsion treatment so as to obtain primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then carrying out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antiserum titer of rabbit arrives at 1 / 10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate. The antibody prepared by the invention has a strong specificity, and can be used for detection and analysis of silk fibroin in textile, and the like.
Owner:ZHEJIANG UNIV +1

Phosphorylcholine conjugates and corresponding antibodies

IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure >95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high autoantibodies particularly high IgM autoantibodies, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM autoantibodies, against phosphorylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH-phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or an antibody preparation, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate (passive immunization) is proposed and the use of these compositions as active or passive immunogens is the treatment or prevention of atherosclerosis.
Owner:ATHERA BIOTECH

Anti-aflatoxin general type monoclonal antibody hybridoma cell line and application thereof

The invention provides an anti-aflatoxin general type monoclonal antibody hybridoma cell line and application thereof, belonging to the field of food safety immunodetection. The cell line 1G6 provided by the invention is collected in the China General Microbiological Culture Collection Center (CGMCC) with a collection number of CGMCC No.7210. After an aflatoxin complete antigen is uniformly mixed with equivalent Quick Antibody immunologic adjuvant TM, an obtained mixture is injected to immunize BALB/c mice through leg muscle. B1-KLH (fumonisin B1-Keyhole Limpet Hemocyanin) is adopted for the first time of immunization, M1-KLH (fumonisin M1-Keyhole Limpet Hemocyanin) is adopted for the second time of immunization, and an M1 complete antigen (without containing adjuvant) is adopted for the last time of impaction immunization. Splenocytes of immunized mice are fused with myeloma cells through a PEG (polyethylene glycol) method, and the hybridoma cell line 1G6 is obtained through indirect ELISA (Enzyme-Linked Immuno Sorbent Assay) and indirect competence ELISA screening and three times of subcloning. A monoclonal antibody secreted from the cell line has better affinity and detection sensitivity for aflatoxins B1, B2, G1, G2 and M1, and can be used for immunodetection of the total quantity of the aflatoxins in the food safety.
Owner:无锡迪腾敏生物科技有限公司 +1

Detection and quantitation of 8-OH-adenine using monoclonal antibodies

The present invention relates to methods and materials for the detection and quantitation 8-OH-Ade in biological specimens. Specifically, the present invention is directed to a group of highly specific monoclonal antibodies reactive with the modified nucleoside structure 8-OH-Ade, and to various immunoassays for 8-OH-Ade utilizing these monoclonal antibodies. The monoclonal antibodies of the present invention may be used in assays for diagnosing or monitoring the progression of certain types of cancer, in addition to a variety of other diseases associated with mutagenesis resulting from oxidative damage of DNA. Assays utilizing the monoclonal antibodies of the present invention may also be used to analyze or monitor toxicant exposure, such as from environmental sources. The monoclonal antibodies of the present invention were prepared with the immunogen 8-OH-adenosine coupled to keyhole limpet hemocyanin (KLH), not to 8-OH-Ade directly. It is believed that the monoclonal antibodies bind with the base portion of the structure (8-OH-Ade) and not the carbohydrate (ribose) or protein linkage region of the conjugate, because, as demonstrated, conjugates bound to nucleosides other than 8-OH-adenosine were unreactive with these antibodies. Therefore, the antibodies of the present invention can be used to detect and quantitate (by the use of a standard curve) the presence of 8-OH-Ade in biological specimens of DNA. Procedures for such an assay include immobilizing the DNA, denaturing it to disrupt the base-pairing scheme exposing the free base structures, and quantitating the amount of 8-OH-Ade present per amount of DAN in a quantitative immunoassay.
Owner:CYTOCHEM

Preparation method of beta2-microglobulin monoclonal antibody

The invention discloses a preparation method of a beta2-microglobulin monoclonal antibody. The method comprises the following steps: firstly, screening out two polypeptide epitope sequences with relatively strong immunogenicity as a first antigen epitope and a second antigen epitope respectively; then respectively connecting one cysteine to each carbon-terminal amino acid of the first antigen epitope and the second antigen epitope, and coupling sulfydryl of the cysteine with primary amino of keyhole limpet hemocyanin through an SMCC coupling method so as to obtain an in-vitro synthesized beta2-MG double-epitope polypeptide antigen; then carrying out conventional immunization on the mouse by utilizing the double-epitope polypeptide antigen, and separating out splenic lymphocytes and myelomacells to carry out cell fusion; and finally, screening out positive monoclonal cells, and extracting monoclonal antibody through intraperitoneal injection and ascites recovery. By improving traditional single-epitope antigen immunization methods, the method optimizes the immunogenicity of the antigen, shortens the immunization period, and improves the serum titer in the immunization stage, thereby improving the obtaining efficiency of the positive monoclonal antibody against beta2-MG.
Owner:上海钹乐诗生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products